HGH Fragment 176-191

Overview

HGH Fragment 176-191, also known as AOD9604, is a modified peptide fragment of human growth hormone (HGH). Specifically, it represents amino acids 176-191 of the HGH polypeptide. It was designed to mimic the fat-burning effects of natural HGH without some of its undesirable effects.

This fragment targets fat metabolism by enhancing lipolysis (the breakdown of fat) and inhibiting lipogenesis (the formation of fat). It is purported to do so without affecting insulin sensitivity or promoting growth, unlike full-length HGH.

HGH Fragment 176-191 is primarily researched for its potential in weight loss and obesity management. It is being investigated for its ability to reduce abdominal fat and improve body composition. Note that research and regulatory approval vary by region.

Mechanism of Action

HGH Fragment 176-191 works by mimicking the way natural human growth hormone regulates fat metabolism. It stimulates lipolysis by increasing the activity of beta-3 adrenergic receptors, which play a key role in fat breakdown. Simultaneously, it inhibits lipogenesis by reducing the activity of the enzyme fatty acid synthase, which is responsible for synthesizing new fatty acids.

Unlike full HGH, Fragment 176-191 does not bind to growth hormone receptors, thus it is not believed to promote growth of bone or cartilage or affect insulin sensitivity. This selective action is thought to minimize some of the potential side effects associated with HGH use.

The peptide's action is primarily targeted at adipose tissue, particularly in the abdominal area, leading to a reduction in body fat stores.

Key Benefits

• Promotes fat loss
• Reduces abdominal fat
• Improves body composition
• Does not affect blood sugar or growth

Research & Indications

Research on HGH Fragment 176-191 has focused on its potential as an anti-obesity drug. Studies have indicated that it can significantly reduce abdominal fat mass in overweight and obese individuals. Clinical trials have explored its efficacy in reducing body weight and improving lipid profiles.

Some research suggests that Fragment 176-191 may also have cartilage regenerative properties and could be used in the treatment of osteoarthritis, although this is less well-established than its fat-burning effects.

Further research is ongoing to fully understand the long-term effects and potential therapeutic applications of HGH Fragment 176-191.

Dosing Protocols

Disclaimer: The following dosing information is not medical advice. Consult with a qualified healthcare professional before using HGH Fragment 176-191.

Typical dosing for HGH Fragment 176-191:

Supplies Needed

For an 8-16 week protocol:

• Peptide Vials: 2-4 vials of 5mg each, or 4-8 vials of 2mg each
• Insulin Syringes (U-100): Approximately 50-100 syringes (depending on frequency of injections)
• Bacteriostatic Water: 1-2 × 10mL bottles
• Alcohol Swabs: One for vial + one for injection site daily

Side Effects & Safety

Common side effects reported with HGH Fragment 176-191 include injection site reactions (redness, itching, or pain). Some individuals may experience mild fatigue or lethargy. As it does not bind to the growth hormone receptor, it is generally considered to have a lower risk of side effects compared to full-length HGH.

However, long-term safety data is limited, and potential risks associated with chronic use are not fully understood. Individuals with pre-existing medical conditions, particularly those related to metabolism or hormone function, should exercise caution.

Storage & Handling

HGH Fragment 176-191 should be stored in lyophilized (freeze-dried) form at -20°C (freezer) for long-term storage. Once reconstituted with bacteriostatic water, it should be refrigerated at 2-8°C and used within a few weeks.